Astrazeneca Stock Today

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>AP</div>
Astrazeneca PLC is selling for 53.68 as of the 2nd of July 2020. This is 0.68 percent up since the beginning of the trading day. The stock's open price was 53.32. Astrazeneca PLC has less than a 12 % chance of experiencing some financial distress in the next two years of operation and had a very good performance during the last 30 days. Equity ratings for Astrazeneca PLC are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 3rd of April 2020 and ending today, the 2nd of July 2020. Click here to learn more.
Analyze Filter   Report: 23rd of July 2020

12 100 

   Odds of Distress

Astrazeneca PLC Profile

Upcoming quarterly report is expected on the 23rd of July 2020. AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca PLC operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 70600 people. more on Astrazeneca PLC
Astrazeneca PLC Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Astrazeneca PLC SEC Filings
Astrazeneca PLC SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameAstrazeneca PLC
CEOPascal SoriotView All
Thematic Classifications
Active investing themes Astrazeneca PLC currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
showing 2 out of 3 themes  View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Astrazeneca PLC. The Astrazeneca consensus assessment is calculated by taking the average estimates from all of the analysts covering Astrazeneca PLC
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Astrazeneca PLC financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 8 - StrongDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares1.2 B1.3 B
Notably Down
Slightly volatile
Weighted Average Shares Diluted1.2 B1.3 B
Notably Down
Slightly volatile
Net Cash Flow from Operations6.1 B4.9 B
Fairly Up
Slightly volatile
Total Assets66 B61.4 B
Notably Up
Slightly volatile
Total Liabilities47 B46.8 B
Slightly Up
Slightly volatile
Current Assets15.9 B15.6 B
Fairly Up
Slightly volatile
Current Liabilities18.9 B18.1 B
Sufficiently Up
Slightly volatile
Total Debt17.4 B18.2 B
Sufficiently Down
Slightly volatile
Return on Average Assets0.02050.02
Fairly Up
Slightly volatile
Gross Margin0.760.798
Notably Down
Slightly volatile
Asset Turnover0.410.401
Fairly Up
Slightly volatile
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Astrazeneca PLC available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Financial Strength
Astrazeneca PLC financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Astrazeneca PLC success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
AA- ( Average Bond Rating ) Very Strong
  Operating Cash Flow
Astrazeneca PLC (AZN) is traded on BATS Exchange in USA. It is located in 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom and employs 70,600 people. Astrazeneca PLC is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with total capitalization of 118.42 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Astrazeneca PLC's market, we take the total number of its shares issued and multiply it by Astrazeneca PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Astrazeneca PLC runs under Healthcare sector within Drug Manufacturers?General industry. The entity has 2.62 B outstanding shares of which 3.17 M shares are presently shorted by investors with about 0.62 days to cover shorted positions. ASTRAZENECA PLC A has about 6.22 B in cash with 2.97 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37.
Check Astrazeneca PLC Probability Of Bankruptcy

Ownership Allocation (%)

Astrazeneca Stock Price Odds Analysis

Odds Down 53.68HorizonTargetOdds Up 53.68
74.69%30 days
Based on a normal probability distribution, the odds of Astrazeneca PLC to move above the current price in 30 days from now is about 25.16 (This Astrazeneca PLC probability density function shows the probability of Astrazeneca PLC Stock to fall within a particular range of prices over 30 days) .

Astrazeneca Stock Institutional Holders

InstituionSecurity TypeTotal SharesValue
Wellington Management Group LlpCommon Shares67.4 MB
Primecap Management CoCommon Shares56.6 M2.5 B
View Astrazeneca PLC Diagnostics

Astrazeneca PLC Income Statement Over Time

Astrazeneca PLC Income Statement is one of the three primary financial statements used for reporting Astrazeneca's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Astrazeneca PLC revenue and expense. Astrazeneca PLC Income Statement primarily focuses on the company's revenues and expenses during a particular period. Astrazeneca PLC Operating Income is quite stable at the moment as compared to the past year. The company's current value of Operating Income is estimated at about 4.12 Billion. Research and Development Expense is projected to rise to about 6.4 B this year, although the value of Cost of Revenue will most likely fall to about 4.8 B. View More Fundamentals

Astrazeneca Stock Against Markets

Did you try this?

Run My Watchlist Analysis Now


My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
All  Next Launch Module

Astrazeneca PLC Upcoming and Recent Events

Astrazeneca PLC Company Earnings Announcements Dates

Upcoming Quarterly Report23rd of July 2020
Next Earnings Report22nd of October 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End12th of February 2021
Last Quarter Report31st of March 2020
Last Earning Anouncement30th of June 2019

Astrazeneca PLC Corporate Filings

Astrazeneca PLC SEC Reporting

Other Events
Unclassified Corporate Event

Astrazeneca PLC Distributions to stockholders

A dividend is the distribution of a portion of Astrazeneca PLC earnings, decided and managed by the Astrazeneca PLCs board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Astrazeneca PLC dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment.
27th of February 2020
8th of August 2019
28th of February 2019
9th of August 2018

Astrazeneca PLC Corporate Directors

Marc Dunoyer Chief Financial Officer, Executive Director
Sherilyn McCoy Non-Executive Independent Director
Genevieve Berger Non-Executive Independent Director
Please continue to Trending Equities. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page